Ten highly specific monoclonal antibodies towards adalimumab were generated.
Two adalimumab ELISAs were developed, showed equal characteristics and had excellent agreement with two available ELISAs.
Comparative studies using different adalimumab assays will facilitate implementation of treatment algorithms.